Last reviewed · How we verify
Atezolizumab and Talazoparib (atezolizumab-and-talazoparib)
Atezolizumab and Talazoparib (generic name: atezolizumab-and-talazoparib) is a Monoclonal antibody drug developed by Pfizer Inc.. It is currently in Phase 2 development.
Atezolizumab binds to PD-L1, blocking its interaction with PD-1 and B7.1, enhancing T-cell activation, while Talazoparib inhibits PARP enzymes, leading to DNA damage accumulation and cancer cell death.
At a glance
| Generic name | atezolizumab-and-talazoparib |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Monoclonal antibody |
| Phase | Phase 2 |
Mechanism of action
Atezolizumab works by binding to PD-L1, a protein that can suppress the immune system, thereby enhancing the body's immune response against cancer cells. Talazoparib, on the other hand, blocks PARP enzymes, which are crucial for repairing damaged DNA in cancer cells, leading to their death.
Approved indications
Common side effects
Key clinical trials
- Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker (PHASE2)
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (PHASE2)
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer (PHASE1, PHASE2)
- Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC (PHASE2)
- The Drug Rediscovery Protocol (DRUP Trial) (PHASE2)
- A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer (PHASE2)
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (PHASE2)
- Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atezolizumab and Talazoparib CI brief — competitive landscape report
- Atezolizumab and Talazoparib updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about Atezolizumab and Talazoparib
What is Atezolizumab and Talazoparib?
How does Atezolizumab and Talazoparib work?
Who makes Atezolizumab and Talazoparib?
What is the generic name of Atezolizumab and Talazoparib?
What development phase is Atezolizumab and Talazoparib in?
Related
- Manufacturer: Pfizer Inc. — full pipeline
- Compare: Atezolizumab and Talazoparib vs similar drugs
- Pricing: Atezolizumab and Talazoparib cost, discount & access